While there are no FDA approved FAK inhibitors, BI-853520/IN-10018, defactinib, CEP-37440, GSK2256098, and PF-00562271 are clinical stage FAK inhibitors +/− dual kinase inhibitory activity under evaluation for various metastatic cancers [198–206]. Here, PTK2 is linked to metastatic malignant neoplasm.